,address1,address2,city,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,exDividendDate,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,GustavslundsvAegen 42,5th Floor,Bromma,167 51,Sweden,46 8 52 23 07 00,46 87 35 20 29,https://www.mobergpharma.se,Drug Manufacturers—Specialty & Generic,Healthcare,"Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products in Europe, the United States, and internationally. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.",9,"{'maxAge': 1, 'name': 'Ms. Kerstin Valinder Strinnholm', 'age': 62, 'title': 'Independent Exec. Chairman', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 210000, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,9.2,8.95,7.95,8.95,9.2,8.95,7.95,8.95,1572825600,0.0,0.945195,-5.408163,1353977,1353977,660914,755574,755574,8.05,8.1,0,0,217011936,2.155,32.2,1048.3668,8.099,20.06675,0.0,0.0,SEK,51731284,0.0,9082763,27297100,0.35154998,0.05286,53.502,0.14859258,1672444800,1703980800,1688083200,-16245000,-1.01,-1.47,249.91,-2.503,STO,EQUITY,MOB.ST,MOB.ST,Moberg Pharma AB,Moberg Pharma AB (publ),1306393200,Europe/Stockholm,CEST,7200000,7.95,19.33,19.33,19.33,19.33,none,1,51951000,5.287,-20668000,4430000,2.603,2.603,207000,0.843,0.022,-0.025009999,-0.030480001,207000,-85937752,-21604000,1.0,0.0,-106.86472,SEK,
1,GustavslundsvAegen 42,5th Floor,Bromma,167 51,Sweden,46 8 52 23 07 00,46 87 35 20 29,https://www.mobergpharma.se,Drug Manufacturers—Specialty & Generic,Healthcare,"Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products in Europe, the United States, and internationally. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.",9,"{'maxAge': 1, 'name': 'Ms. Anna  Ljung BA, M.Sc.', 'age': 42, 'title': 'Chief Exec. Officer', 'yearBorn': 1980, 'fiscalYear': 2022, 'totalPay': 2474000, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,9.2,8.95,7.95,8.95,9.2,8.95,7.95,8.95,1572825600,0.0,0.945195,-5.408163,1353977,1353977,660914,755574,755574,8.05,8.1,0,0,217011936,2.155,32.2,1048.3668,8.099,20.06675,0.0,0.0,SEK,51731284,0.0,9082763,27297100,0.35154998,0.05286,53.502,0.14859258,1672444800,1703980800,1688083200,-16245000,-1.01,-1.47,249.91,-2.503,STO,EQUITY,MOB.ST,MOB.ST,Moberg Pharma AB,Moberg Pharma AB (publ),1306393200,Europe/Stockholm,CEST,7200000,7.95,19.33,19.33,19.33,19.33,none,1,51951000,5.287,-20668000,4430000,2.603,2.603,207000,0.843,0.022,-0.025009999,-0.030480001,207000,-85937752,-21604000,1.0,0.0,-106.86472,SEK,
2,GustavslundsvAegen 42,5th Floor,Bromma,167 51,Sweden,46 8 52 23 07 00,46 87 35 20 29,https://www.mobergpharma.se,Drug Manufacturers—Specialty & Generic,Healthcare,"Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products in Europe, the United States, and internationally. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.",9,"{'maxAge': 1, 'name': 'Ms. Marie  Moberg', 'title': 'Co-Founder', 'fiscalYear': 2009, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,9.2,8.95,7.95,8.95,9.2,8.95,7.95,8.95,1572825600,0.0,0.945195,-5.408163,1353977,1353977,660914,755574,755574,8.05,8.1,0,0,217011936,2.155,32.2,1048.3668,8.099,20.06675,0.0,0.0,SEK,51731284,0.0,9082763,27297100,0.35154998,0.05286,53.502,0.14859258,1672444800,1703980800,1688083200,-16245000,-1.01,-1.47,249.91,-2.503,STO,EQUITY,MOB.ST,MOB.ST,Moberg Pharma AB,Moberg Pharma AB (publ),1306393200,Europe/Stockholm,CEST,7200000,7.95,19.33,19.33,19.33,19.33,none,1,51951000,5.287,-20668000,4430000,2.603,2.603,207000,0.843,0.022,-0.025009999,-0.030480001,207000,-85937752,-21604000,1.0,0.0,-106.86472,SEK,
3,GustavslundsvAegen 42,5th Floor,Bromma,167 51,Sweden,46 8 52 23 07 00,46 87 35 20 29,https://www.mobergpharma.se,Drug Manufacturers—Specialty & Generic,Healthcare,"Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products in Europe, the United States, and internationally. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.",9,"{'maxAge': 1, 'name': 'Mr. Mark  Beveridge', 'age': 44, 'title': 'VP of Fin.', 'yearBorn': 1978, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,9.2,8.95,7.95,8.95,9.2,8.95,7.95,8.95,1572825600,0.0,0.945195,-5.408163,1353977,1353977,660914,755574,755574,8.05,8.1,0,0,217011936,2.155,32.2,1048.3668,8.099,20.06675,0.0,0.0,SEK,51731284,0.0,9082763,27297100,0.35154998,0.05286,53.502,0.14859258,1672444800,1703980800,1688083200,-16245000,-1.01,-1.47,249.91,-2.503,STO,EQUITY,MOB.ST,MOB.ST,Moberg Pharma AB,Moberg Pharma AB (publ),1306393200,Europe/Stockholm,CEST,7200000,7.95,19.33,19.33,19.33,19.33,none,1,51951000,5.287,-20668000,4430000,2.603,2.603,207000,0.843,0.022,-0.025009999,-0.030480001,207000,-85937752,-21604000,1.0,0.0,-106.86472,SEK,
4,GustavslundsvAegen 42,5th Floor,Bromma,167 51,Sweden,46 8 52 23 07 00,46 87 35 20 29,https://www.mobergpharma.se,Drug Manufacturers—Specialty & Generic,Healthcare,"Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products in Europe, the United States, and internationally. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.",9,"{'maxAge': 1, 'name': 'Gunilla  Wengström', 'title': 'Sr. Director of Sales & Marketing', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,9.2,8.95,7.95,8.95,9.2,8.95,7.95,8.95,1572825600,0.0,0.945195,-5.408163,1353977,1353977,660914,755574,755574,8.05,8.1,0,0,217011936,2.155,32.2,1048.3668,8.099,20.06675,0.0,0.0,SEK,51731284,0.0,9082763,27297100,0.35154998,0.05286,53.502,0.14859258,1672444800,1703980800,1688083200,-16245000,-1.01,-1.47,249.91,-2.503,STO,EQUITY,MOB.ST,MOB.ST,Moberg Pharma AB,Moberg Pharma AB (publ),1306393200,Europe/Stockholm,CEST,7200000,7.95,19.33,19.33,19.33,19.33,none,1,51951000,5.287,-20668000,4430000,2.603,2.603,207000,0.843,0.022,-0.025009999,-0.030480001,207000,-85937752,-21604000,1.0,0.0,-106.86472,SEK,
5,GustavslundsvAegen 42,5th Floor,Bromma,167 51,Sweden,46 8 52 23 07 00,46 87 35 20 29,https://www.mobergpharma.se,Drug Manufacturers—Specialty & Generic,Healthcare,"Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products in Europe, the United States, and internationally. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.",9,"{'maxAge': 1, 'name': 'Anders  Broijersen M.D., Ph.D.', 'age': 58, 'title': 'Chief Medical Officer', 'yearBorn': 1964, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,9.2,8.95,7.95,8.95,9.2,8.95,7.95,8.95,1572825600,0.0,0.945195,-5.408163,1353977,1353977,660914,755574,755574,8.05,8.1,0,0,217011936,2.155,32.2,1048.3668,8.099,20.06675,0.0,0.0,SEK,51731284,0.0,9082763,27297100,0.35154998,0.05286,53.502,0.14859258,1672444800,1703980800,1688083200,-16245000,-1.01,-1.47,249.91,-2.503,STO,EQUITY,MOB.ST,MOB.ST,Moberg Pharma AB,Moberg Pharma AB (publ),1306393200,Europe/Stockholm,CEST,7200000,7.95,19.33,19.33,19.33,19.33,none,1,51951000,5.287,-20668000,4430000,2.603,2.603,207000,0.843,0.022,-0.025009999,-0.030480001,207000,-85937752,-21604000,1.0,0.0,-106.86472,SEK,
6,GustavslundsvAegen 42,5th Floor,Bromma,167 51,Sweden,46 8 52 23 07 00,46 87 35 20 29,https://www.mobergpharma.se,Drug Manufacturers—Specialty & Generic,Healthcare,"Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products in Europe, the United States, and internationally. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.",9,"{'maxAge': 1, 'name': 'Mr. Jesper  Lind', 'age': 62, 'title': 'Head of Supply', 'yearBorn': 1960, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,9.2,8.95,7.95,8.95,9.2,8.95,7.95,8.95,1572825600,0.0,0.945195,-5.408163,1353977,1353977,660914,755574,755574,8.05,8.1,0,0,217011936,2.155,32.2,1048.3668,8.099,20.06675,0.0,0.0,SEK,51731284,0.0,9082763,27297100,0.35154998,0.05286,53.502,0.14859258,1672444800,1703980800,1688083200,-16245000,-1.01,-1.47,249.91,-2.503,STO,EQUITY,MOB.ST,MOB.ST,Moberg Pharma AB,Moberg Pharma AB (publ),1306393200,Europe/Stockholm,CEST,7200000,7.95,19.33,19.33,19.33,19.33,none,1,51951000,5.287,-20668000,4430000,2.603,2.603,207000,0.843,0.022,-0.025009999,-0.030480001,207000,-85937752,-21604000,1.0,0.0,-106.86472,SEK,
7,GustavslundsvAegen 42,5th Floor,Bromma,167 51,Sweden,46 8 52 23 07 00,46 87 35 20 29,https://www.mobergpharma.se,Drug Manufacturers—Specialty & Generic,Healthcare,"Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products in Europe, the United States, and internationally. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.",9,"{'maxAge': 1, 'name': 'Dr. Agneta  Larhed', 'age': 58, 'title': 'VP of Pharmaceutical Innovation & Devel.', 'yearBorn': 1964, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,9.2,8.95,7.95,8.95,9.2,8.95,7.95,8.95,1572825600,0.0,0.945195,-5.408163,1353977,1353977,660914,755574,755574,8.05,8.1,0,0,217011936,2.155,32.2,1048.3668,8.099,20.06675,0.0,0.0,SEK,51731284,0.0,9082763,27297100,0.35154998,0.05286,53.502,0.14859258,1672444800,1703980800,1688083200,-16245000,-1.01,-1.47,249.91,-2.503,STO,EQUITY,MOB.ST,MOB.ST,Moberg Pharma AB,Moberg Pharma AB (publ),1306393200,Europe/Stockholm,CEST,7200000,7.95,19.33,19.33,19.33,19.33,none,1,51951000,5.287,-20668000,4430000,2.603,2.603,207000,0.843,0.022,-0.025009999,-0.030480001,207000,-85937752,-21604000,1.0,0.0,-106.86472,SEK,
